{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:41Z","timestamp":1787071061373,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Compared with other lung squamous cell carcinomas (LUSC), pulmonary lymphoepithelioma-like carcinoma (pLELC) is closely associated with Epstein\u2013Barr virus (EBV) infections with a unique molecular profile and immune microenvironment. This study was thus established to compare the treatment response and effectiveness of immunotherapy between pLELC and LUSC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>We enrolled 31 patients with pLELC and 116 with LUSC receiving first-line immunotherapy at three centers in China and compared the treatment response and effectiveness of immunotherapy. Propensity score matching (PSM) was used to balance the differences in baseline data between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Before PSM, progression-free survival and overall survival were longer in the pLELC group than in the LUSC group (progression-free survival: hazard ratio (HR), 1.67, 95% CI: 1.05\u20132.63,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.028; overall survival: HR, 1.90, 95% CI: 1.06\u20133.40, P = 0.028). This remained unchanged after PSM (progression-free survival: HR, 1.79, 95% CI: 1.02\u20133.15,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.044; overall survival: HR, 2.20; 95% CI: 1.10\u20134.37,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.022).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>pLELC showed a clinically meaningful survival benefit compared with traditional LUSC following immunotherapy. Subsequent studies should consider the role of the EBV in the tumor immune microenvironment of pLELC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2711_22","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T12:01:33Z","timestamp":1693224093000},"page":"1011-1018","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of first-line immunotherapy efficacy between advanced lung squamous cell carcinoma and pulmonary lymphoepithelioma-like carcinoma: A propensity score matching multicenter study"],"prefix":"10.4103","volume":"19","author":[{"given":"YuBin","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Cardio-Thoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China"},{"name":"The University of Hongkong-ShenZhen Hospital, Shenzhen, 518000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, the People\u2019s Hospital of Gaoan City. Gaoan, Jiangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiation Therapy, General Hospital of Southern Theater Command, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Yuan","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Guangdong Medical University, Dongguan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longyan","family":"Dong","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Guangdong Medical University, Dongguan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, the Third Xiangya Hospital, Central South University, Chang-sha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-ao","family":"Yue","sequence":"additional","affiliation":[{"name":"Huafa Community Health Service Center, Shenzhen, Zhuhai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Cardio-Thoracic Surgery, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongwen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China"},{"name":"School of Medicine, South China University of Technology, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20241021","doi-asserted-by":"crossref","DOI":"10.4103\/jcrt.jcrt_276_22","article-title":"Online public interest in smoking and lung cancer:A comparative study in google trends","author":"Tas","year":"2023","journal-title":"J Can Res Ther"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat Med"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jtho.2020.09.015","article-title":"Long-term overall survival from KEYNOTE-021 Cohort G:Pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC","volume":"16","author":"Awad","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC:Protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R7-20241021","doi-asserted-by":"crossref","DOI":"10.4103\/jcrt.jcrt_1103_22","article-title":"Diagnosing lung cancer at a younger age and with male dominance:Comparison of Turkish patients with United States patients","author":"Tas","year":"2023","journal-title":"J Can Res Ther"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4103\/jcrt.jcrt_855_21","article-title":"Effectiveness and safety of camrelizumab combined with chemotherapy in nonsquamous nonsmall cell lung cancer as the second-line therapy:A retrospective analysis","volume":"18","author":"Wei","year":"2022","journal-title":"J Can Res Ther"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"664","DOI":"10.4103\/jcrt.JCRT_195_20","article-title":"EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations:A meta-analysis of randomized controlled trials","volume":"17","author":"Cui-Min","year":"2021","journal-title":"J Can Res Ther"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189:Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors:Impact of genetic, clinical and radiologic advances since the 2004 Classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R14-20241021","first-page":"986","article-title":"Circulating Epstein-Barr virus DNA in serum of patients with lymphoepithelioma-like carcinoma of the lung:A potential surrogate marker for monitoring disease","volume":"8","author":"Ngan","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/modpathol.2009.7","article-title":"Epstein-Barr virus-associated adenocarcinomas and squamous-cell lung carcinomas","volume":"22","author":"Gomez-Roman","year":"2009","journal-title":"Mod Pathol"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/jso.2930360413","article-title":"Epstein-Barr virus related lymphoepithelioma-like carcinoma of lung","volume":"36","author":"Begin","year":"1987","journal-title":"J Surg Oncol"},{"key":"R17-20241021","article-title":"WHO Classification of Tumours of the Lung, Plura, Thymus and Heart","author":"Travis WD Brambilla","year":"2015","journal-title":"IARC Publications"},{"key":"R18-20241021","year":"2021","journal-title":"IARC Publications"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1182\/blood-2014-11-599951","article-title":"The tumor virus landscape of AIDS-related lymphomas","volume":"125","author":"Arvey","year":"2015","journal-title":"Blood"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","article-title":"Defective Epstein-Barr virus in chronic active infection and haematological malignancy","volume":"4","author":"Okuno","year":"2019","journal-title":"Nat Microbiol"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"e43653","DOI":"10.7554\/eLife.43653","article-title":"CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors","volume":"8","author":"Walens","year":"2019","journal-title":"Elife"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3324\/haematol.2018.196725","article-title":"CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth","volume":"104","author":"Casagrande","year":"2019","journal-title":"Haematologica"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.1096781","article-title":"Identification of virus-encoded microRNAs","volume":"304","author":"Pfeffer","year":"2004","journal-title":"Science"},{"key":"R24-20241021","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1158\/0008-5472.CAN-07-5126","article-title":"EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3","volume":"68","author":"Xia","year":"2008","journal-title":"Cancer Res"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"E6467","DOI":"10.1073\/pnas.1605884113","article-title":"Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+T cells","volume":"113","author":"Albanese","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R26-20241021","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1038\/s41467-019-10902-w","article-title":"The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma","volume":"10","author":"Hong","year":"2019","journal-title":"Nat Commun"},{"key":"R27-20241021","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41392-020-00382-6","article-title":"Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R28-20241021","doi-asserted-by":"crossref","first-page":"153043","DOI":"10.1016\/j.prp.2020.153043","article-title":"Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden","volume":"216","author":"Wu","year":"2020","journal-title":"Pathol Res Pract"},{"key":"R29-20241021","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41379-019-0391-9","article-title":"A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung","volume":"33","author":"Xie","year":"2020","journal-title":"Mod Pathol"},{"key":"R30-20241021","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41586-019-1330-0","article-title":"Immune evasion before tumour invasion in early lung squamous carcinogenesis","volume":"571","author":"Mascaux","year":"2019","journal-title":"Nature"},{"key":"R31-20241021","doi-asserted-by":"crossref","first-page":"820302","DOI":"10.3389\/fonc.2022.820302","article-title":"Comparison of immunotherapy, chemotherapy, and chemoimmunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma:A retrospective study","volume":"12","author":"Xiao","year":"2022","journal-title":"Front Oncol"},{"key":"R32-20241021","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project:Proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R33-20241021","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R34-20241021","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4103\/jcrt.JCRT_450_19","article-title":"Checkpoint inhibitors in advanced nonsmall-cell lung cancer;a Bayesian network meta-analysis","volume":"16","author":"Hakan","year":"2020","journal-title":"J Can Res Ther"},{"key":"R35-20241021","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-019-0743-4","article-title":"Immune checkpoint inhibitors in the treatment of virus-associated cancers","volume":"12","author":"Gao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R36-20241021","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and lytic replication in Epstein-Barr virus-associated oncogenesis","volume":"17","author":"M\u00fcnz","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"R37-20241021","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"R38-20241021","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012):A multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"key":"R39-20241021","doi-asserted-by":"crossref","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:Phase 2 Clinical KEYNOTE-059 Trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"R40-20241021","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/cas.13954","article-title":"Epstein-Barr virus strain variation and cancer","volume":"110","author":"Kanda","year":"2019","journal-title":"Cancer Sci"},{"key":"R41-20241021","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018:A worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"R42-20241021","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042):A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"R43-20241021","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"R44-20241021","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"R45-20241021","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jtho.2021.03.016","article-title":"Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC:A systematic review and network meta-analysis","volume":"16","author":"Liu","year":"2021","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2711_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:56Z","timestamp":1787067656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2711_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2711_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"2022-12-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}